...
vktx-img

Viking Therapeutics Inc, Common Stock

VKTX

NAQ

$41.49

+$3.21

(8.39%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.20B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
6.99M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.99
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$17.23 L
$99.41 H
$41.49

About Viking Therapeutics Inc, Common Stock

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVKTXSectorS&P500
1-Week Return-13.33%-3.35%-2.97%
1-Month Return-19.45%-3.49%-0.66%
3-Month Return-39.13%-12.6%2.71%
6-Month Return-17.73%-6.91%7.21%
1-Year Return116.66%1.19%23.04%
3-Year Return738.18%-0.21%28.43%
5-Year Return419.27%33.09%82.88%
10-Year Return363.06%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-10.73K10.70K--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.72,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue260.00K277.00K296.00K291.00K292.00K[{"date":"2019-12-31","value":87.84,"profit":true},{"date":"2020-12-31","value":93.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.31,"profit":true},{"date":"2023-12-31","value":98.65,"profit":true}]
Gross Profit(260.00K)10.73K(296.00K)(291.00K)(292.00K)[{"date":"2019-12-31","value":-2422.89,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2758.36,"profit":false},{"date":"2022-12-31","value":-2711.77,"profit":false},{"date":"2023-12-31","value":-2721.09,"profit":false}]
Gross Margin-100.00%(2766.10%)--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2766.1,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses32.69M42.66M55.68M70.36M100.83M[{"date":"2019-12-31","value":32.42,"profit":true},{"date":"2020-12-31","value":42.31,"profit":true},{"date":"2021-12-31","value":55.23,"profit":true},{"date":"2022-12-31","value":69.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(32.69M)(42.66M)(55.68M)(70.36M)(100.83M)[{"date":"2019-12-31","value":-3268700000,"profit":false},{"date":"2020-12-31","value":-4266200000,"profit":false},{"date":"2021-12-31","value":-5568200000,"profit":false},{"date":"2022-12-31","value":-7035500000,"profit":false},{"date":"2023-12-31","value":-10082700000,"profit":false}]
Total Non-Operating Income/Expense13.81M45.75M1.38M3.02M25.91M[{"date":"2019-12-31","value":30.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.01,"profit":true},{"date":"2022-12-31","value":6.6,"profit":true},{"date":"2023-12-31","value":56.63,"profit":true}]
Pre-Tax Income(25.78M)(39.49M)(54.99M)(68.87M)(85.89M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6886700000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}]
Income Taxes(4.00K)(3.48M)(988.00K)(1.49M)(292.00K)[{"date":"2019-12-31","value":-400000,"profit":false},{"date":"2020-12-31","value":-348400000,"profit":false},{"date":"2021-12-31","value":-98800000,"profit":false},{"date":"2022-12-31","value":-148800000,"profit":false},{"date":"2023-12-31","value":-29200000,"profit":false}]
Income After Taxes(25.77M)(36.01M)(54.00M)(67.38M)(85.60M)[{"date":"2019-12-31","value":-2577500000,"profit":false},{"date":"2020-12-31","value":-3601100000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":-8560300000,"profit":false}]
Income From Continuous Operations(25.78M)(39.49M)(54.99M)(69.13M)(80.85M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6912500000,"profit":false},{"date":"2023-12-31","value":-8084900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(25.78M)(39.49M)(54.00M)(67.38M)(85.89M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}]
EPS (Diluted)(0.36)(0.54)(0.72)(0.91)(0.92)[{"date":"2019-12-31","value":-36,"profit":false},{"date":"2020-12-31","value":-54,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-92,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VKTX
Cash Ratio 36.23
Current Ratio 36.47

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VKTX
ROA (LTM) -12.68%
ROE (LTM) -15.50%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VKTX
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VKTX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 5.71
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Viking Therapeutics Inc share price today?

Viking Therapeutics Inc (VKTX) share price today is $41.49

Can Indians buy Viking Therapeutics Inc shares?

Yes, Indians can buy shares of Viking Therapeutics Inc (VKTX) on Vested. To buy Viking Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Viking Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Viking Therapeutics Inc (VKTX) via the Vested app. You can start investing in Viking Therapeutics Inc (VKTX) with a minimum investment of $1.

How to invest in Viking Therapeutics Inc shares from India?

You can invest in shares of Viking Therapeutics Inc (VKTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in VKTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Viking Therapeutics Inc shares
What is Viking Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Viking Therapeutics Inc (VKTX) is $99.41. The 52-week low price of Viking Therapeutics Inc (VKTX) is $17.23.

What is Viking Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Viking Therapeutics Inc (VKTX) is

What is Viking Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Viking Therapeutics Inc (VKTX) is 5.71

What is Viking Therapeutics Inc dividend yield?

The dividend yield of Viking Therapeutics Inc (VKTX) is 0.00%

What is the Market Cap of Viking Therapeutics Inc?

The market capitalization of Viking Therapeutics Inc (VKTX) is $5.20B

What is Viking Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Viking Therapeutics Inc is VKTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top